Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report) – Leerink Partners ranks Q3 2025 for shares of Tandem Diabetes Care in a research report issued to clients and investors on Thursday, February 22nd. We have announced our earnings forecast. Leerink Partners analyst M. Kratky predicts that the medical device company will post his earnings per share this quarter. Tandem Diabetes Care’s current consensus estimate for full-year earnings is $1.38 per share. Leerink Partners also announced his expectations for Tandem Diabetes Care’s fourth quarter 2025 earnings of $0.05 EPS and fiscal 2028 earnings of $0.51 EPS.
Other research analysts have also recently published research reports on the stock. Piper Sandler lowered their target price on shares of Tandem Diabetes Care from $40.00 to $25.00 and gave the stock an “overweight” rating in a research note on Thursday, November 2nd. Stifel Nicolaus increased their target price on shares of Tandem Diabetes Care from $17.00 to $24.00 and gave the company a “hold” rating in a research note on Monday, February 5th. Finally, StockNews.com upgraded shares of Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research note on Thursday, January 4th. One investment analyst has rated the stock as a “sell,” nine have rated it a “hold,” and four have rated it a “buy.” The company has an average rating of “Hold” and an average price target of $36.23, according to data from MarketBeat.com.
Read the latest report on Tandem Diabetes Care
Tandem Diabetes Care Transactions Up 16.5%
Tandem Diabetes Care shares opened at $29.13 on Friday. The company’s 50 day simple moving average is $25.82 and its 200 day simple moving average is $23.22. The stock has a market capitalization of $1.9 billion, a P/E ratio of -8.47, and a beta of 1.11. Tandem Diabetes Care has a 1-year low of $13.82 and a 1-year high of $44.85. The company has a debt-equity ratio of 0.91, a current ratio of 4.05, and a quick ratio of 3.28.
Insider buying and selling at Tandem Diabetes Care
In other Tandem Diabetes Care news, Director Dick Allen purchased 5,000 shares of Tandem Diabetes Care stock in a transaction on Monday, November 27th. The shares were purchased at an average price of $18.96 per share, for a total transaction of $94,800.00. Following the acquisition, the director now directly owns 19,962 shares of the company’s stock, valued at approximately $378,479.52. The acquisition was disclosed in a filing with the SEC, which can be accessed on the SEC’s website. 2.50% of the shares are currently owned by insiders.
Hedge funds also pay attention to diabetes treatment tandem
A major investor recently changed his position within the company. Paradise Investment Management LLC increased its holdings in shares of Tandem Diabetes Care by 23.9% during the 3rd quarter. Paradise Investment Management LLC now owns 1,520,065 shares of the medical device company’s stock valued at $31,572,000 after purchasing an additional 293,250 shares during the period. Banque Pictet & Cie SA bought a new position in shares of Tandem Diabetes Care during the 3rd quarter valued at approximately $2,295,000. Jennison Associates LLC increased his stake in shares of Tandem Diabetes Care by 252.6% in the 3rd quarter. Jennison Associates LLC now owns 1,122,915 shares of the medical device company’s stock valued at $23,323,000 after purchasing an additional 804,488 shares during the period. Rice Hall James & Associates LLC purchased a new position in shares of Tandem Diabetes Care during the 3rd quarter valued at approximately $2,230,000. Finally, Jump Financial LLC grew its position in Tandem Diabetes Care by 25.2% in the 3rd quarter. Jump Financial LLC now owns 204,230 shares of the medical device company’s stock valued at $4,242,000 after purchasing an additional 41,060 shares during the period.
About Tandem Diabetes Care
(Get Free Report)
Tandem Diabetes Care, Inc. is a medical device company that designs, develops, and commercializes a variety of products for patients with insulin-dependent diabetes in the United States and internationally. The company’s flagship product is a pump platform consisting of the t:slim X2 insulin delivery system, t:slim X2 pump, 300-unit disposable insulin cartridge, and infusion set.
Related item
Receive daily Tandem Diabetes Care news and reviews – Enter your email address below to receive a concise, daily summary of the latest news and analyst ratings for Tandem Diabetes Care and related companies in MarketBeat.com’s free daily email newsletter.
